---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-25-000028"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:53:45.650375+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lisata Q1 net loss $4.7M; cash $25.8M; ASCEND Cohort B oral at ESMO-GI Jul 2025

## Summary
- Net loss $4.7M for Q1 2025, vs $5.4M in Q1 2024; operating expenses down 11% to $5.8M.
- Cash, equivalents, and marketable securities $25.8M as of Mar 31, 2025; runway into Q3 2026.
- Cohort B of ASCEND trial (mPDAC) accepted for oral presentation at ESMO-GI July 2025; final analysis pending.
- BOLSTER trial in first-line cholangiocarcinoma fully enrolled; topline data anticipated mid-2025.
- Qilu's Phase 2 certepetide trial in China complete; Phase 3 start triggers $10M milestone payment.

## SEC filing metadata
- accession: 0000320017-25-000028
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001725000028/0000320017-25-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001725000028/clbs-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-25-000028
- JSON: https://secwatch.observer/filing/0000320017-25-000028.json
- Plain text: https://secwatch.observer/filing/0000320017-25-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.